Literature DB >> 15664354

In vivo rat metabolism and pharmacokinetic studies of ginsenoside Rg3.

Tianxiu Qian1, Zongwei Cai, Ricky N S Wong, Nai Ki Mak, Zhi-Hong Jiang.   

Abstract

Metabolism of an anti-tumor active component of Panax ginseng, ginsenoside (20R)-Rg(3), was studied for better understanding its pharmacokinetics in rat. LC-MS was used to determine Rg(3) and its metabolites in rat plasma, urine and feces samples. An average half-life of 18.5 min was obtained after the ginsenoside was intravenously dosed at 5 mg/kg. However, Rg(3) was not detected in rat plasma collected after oral administration at 100 mg/kg. Only 0.97-1.15% Rg(3) of the dosed amount was determined in feces. Hydrolysis and oxygenated metabolites were detected and identified in feces collected after oral administration by using LC-MS and MS-MS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15664354     DOI: 10.1016/j.jchromb.2004.11.036

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  17 in total

1.  Qualitative analysis of xinyue capsules by high-performance liquid chromatography: Preliminary evaluation of drug quality in a Sino-Austrian joint study.

Authors:  Mei Xue; Lin Yang; Da-zhuo Shi; Christian Radauer; Heimo Breiteneder; Yan Ma
Journal:  Chin J Integr Med       Date:  2015-11-03       Impact factor: 1.978

2.  Pharmacokinetics of Single Ascending Doses and Multiple Doses of 20(S)-Ginsenoside Rg3 in Chinese Healthy Volunteers.

Authors:  Qian Zhao; Pingya Li; Ji Jiang; Pei Hu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-12       Impact factor: 2.441

Review 3.  Bioactivity enhancement of herbal supplements by intestinal microbiota focusing on ginsenosides.

Authors:  Huai-You Wang; Lian-Wen Qi; Chong-Zhi Wang; Ping Li
Journal:  Am J Chin Med       Date:  2011       Impact factor: 4.667

Review 4.  Isolation and analysis of ginseng: advances and challenges.

Authors:  Lian-Wen Qi; Chong-Zhi Wang; Chun-Su Yuan
Journal:  Nat Prod Rep       Date:  2011-01-24       Impact factor: 13.423

5.  Pharmacokinetics and tissue distribution of 25-hydroxyprotopanaxadiol, an anti-cancer compound isolated from Panax ginseng, in athymic mice bearing xenografts of human pancreatic tumors.

Authors:  Miao Hao; Wei Wang; Yuqing Zhao; Ruiwen Zhang; Hui Wang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2010-12-28       Impact factor: 2.441

6.  Biotransformation of ginsenosides Rb1, Rg3 and Rh2 in rat gastrointestinal tracts.

Authors:  Tianxiu Qian; Zongwei Cai
Journal:  Chin Med       Date:  2010-05-26       Impact factor: 5.455

7.  The antitumor activity study of ginsenosides and metabolites in lung cancer cell.

Authors:  Feng-Yuan Xu; Wen-Qing Shang; Jia-Jun Yu; Qian Sun; Ming-Qing Li; Jian-Song Sun
Journal:  Am J Transl Res       Date:  2016-04-15       Impact factor: 4.060

8.  Inhibition of P-glycoprotein leads to improved oral bioavailability of compound K, an anticancer metabolite of red ginseng extract produced by gut microflora.

Authors:  Zhen Yang; Jing-Rong Wang; Tao Niu; Song Gao; Taijun Yin; Ming You; Zhi-Hong Jiang; Ming Hu
Journal:  Drug Metab Dispos       Date:  2012-05-14       Impact factor: 3.922

9.  Effects of protopanaxatriol-ginsenoside metabolites on rat N-methyl-d-aspartic Acid receptor-mediated ion currents.

Authors:  Tae-Joon Shin; Sung-Hee Hwang; Sun-Hye Choi; Byung-Hwan Lee; Jiyeon Kang; Hyeon-Joong Kim; R Suzanne Zukin; Hyewhon Rhim; Seung-Yeol Nah
Journal:  Korean J Physiol Pharmacol       Date:  2012-04-24       Impact factor: 2.016

10.  20(S)-25-methoxyl-dammarane-3beta, 12beta, 20-triol, a novel natural product for prostate cancer therapy: activity in vitro and in vivo and mechanisms of action.

Authors:  W Wang; H Wang; E R Rayburn; Y Zhao; D L Hill; R Zhang
Journal:  Br J Cancer       Date:  2008-02-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.